Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
暂无分享,去创建一个
Saibal Kar | Vivek Y. Reddy | Maurice Buchbinder | Brian Whisenant | Petr Neuzil | Nicole Gordon | David R. Holmes | P. Neužil | J. Halperin | M. Buchbinder | V. Reddy | B. Whisenant | D. Holmes | S. Kar | H. Sievert | K. Huber | Horst Sievert | Jonathan L. Halperin | Shephal K. Doshi | Vijay Swarup | Kenneth C. Huber | S. Doshi | N. Gordon | V. Swarup
[1] D. Packer,et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. , 2006, American heart journal.
[2] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[3] H. Aberg. Atrial fibrillation. I. A study of atrial thrombosis and systemic embolism in a necropsy material. , 2009, Acta medica Scandinavica.
[4] J. Halperin,et al. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. , 2012, European heart journal.
[5] N. Ammash,et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographics tudy , 1995 .
[6] G. Schuler,et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. , 2007, Journal of the American College of Cardiology.
[7] Saibal Kar,et al. Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry , 2011, Circulation.
[8] J. Odell,et al. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.
[9] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[10] Bernhard Meier,et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[11] N. Ammash,et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. , 1995, Journal of the American College of Cardiology.
[12] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[13] David B. Dunson,et al. Bayesian Data Analysis , 2010 .
[14] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[15] R. Stafford,et al. National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011 , 2012, Circulation. Cardiovascular quality and outcomes.
[16] Donald R. Lynch. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[17] C. Robinson-Cohen,et al. The effect of anticoagulants on cancer risk and survival: systematic review. , 2007, Cancer treatment reviews.
[18] G. Wander,et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection In Patients With Atrial Fibrillation) trial. , 2013 .
[19] F. McAlister,et al. Why do patients with atrial fibrillation not receive warfarin? , 2000, Archives of internal medicine.
[20] Jun Zhu,et al. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[21] J. Ruskin,et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.
[22] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[23] Petr Neuzil,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.
[24] M. Lesh,et al. Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation: Early Clinical Experience , 2002, Circulation.
[25] Salim Yusuf,et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[26] P. Neužil,et al. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial , 2013, Circulation.
[27] A. Rabinstein. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2010 .
[28] B. Gage,et al. Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation , 2006, Stroke.